Shoulder Pacemaker for Scapular Dyskinesia

Sponsor
University of Utah (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05116722
Collaborator
(none)
20
1
1
59.1
0.3

Study Details

Study Description

Brief Summary

The investigators purpose of this study is to determine patients-reported outcomes (VAS pain scores) in patients with Scapular Dyskinesis or Posterior Shoulder Instability who undergo rehabilitation with a shoulder pacemaker.

Condition or Disease Intervention/Treatment Phase
  • Device: Shoulder Pacemaker
N/A

Detailed Description

The scapula plays a key role in nearly every aspect of normal shoulder function. Shoulder dyskinesia or scapula winging effects patients as a result of nerve injury or muscle detachment or abnormal muscle recruitment. Patients with abnormal muscle recruitment often are helped the most by therapy but restoring normal firing can be difficult. Abnormal muscle recruitment is due to pain or weakness or instability of the glenohumeral joint and the muscles around the scapula attempt to compensate for the lack of normal firing patterns. In many patients, physical therapy and surgery have proven to be unsuccessful treatment options.

The Shoulder Pacemaker is a device that specifically aims at resolving functional issues that surgery and physical therapy are unable. It's a wearable electro stimulator created for patients suffering from unbalanced muscle activation in the shoulder, such as Scapular Dyskinesis. The Shoulder Pacemaker delivers "smart stimulation" through a dynamic interaction between the patient and the device. The motion technology recognizes muscle movement and automatically sets the appropriate stimulation intensity according to the movement. This process helps to restore normal muscle activation patterns and equilibrium. The pacemaker will hopefully assist in restoring normal muscle recruitment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Shoulder Pacemaker for the Treatment of Scapular Dyskinesia
Actual Study Start Date :
Sep 27, 2021
Anticipated Primary Completion Date :
Sep 1, 2026
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Shoulder Pacemaker Treatment

The patients will be treated using the pacemaker for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.

Device: Shoulder Pacemaker
Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.

Outcome Measures

Primary Outcome Measures

  1. Visual Analog Scale (VAS) pain [Beginning of the study prior to initiating use of the pacemaker]

    VAS pain score (0 no pain - 10 severe pain)

  2. Visual Analog Scale (VAS) pain [3-months]

    VAS pain score (0 no pain - 10 severe pain)

  3. Visual Analog Scale (VAS) pain [6-months]

    VAS pain score (0 no pain - 10 severe pain)

  4. Visual Analog Scale (VAS) pain [12-months]

    VAS pain score (0 no pain - 10 severe pain)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Scapular Dyskinesis

  • Posterior Shoulder Instability

Exclusion Criteria:
  • Rotator Cuff Tearing

  • Shoulder Arthritis

  • Patients with implantable electrical/electronic devices

  • If participants are using wearable electrical medical devices, such as glucose sensors or infusion pumps, these devices will be turned off or the participants will be excluded from the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Of Utah Orthopedics Center Salt Lake City Utah United States 84108

Sponsors and Collaborators

  • University of Utah

Investigators

  • Principal Investigator: Robert Z Tashjian, MD, University of Utah Orthopaedics

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Robert Tashjian, Principle Investigator, University of Utah
ClinicalTrials.gov Identifier:
NCT05116722
Other Study ID Numbers:
  • 144053
First Posted:
Nov 11, 2021
Last Update Posted:
Jun 24, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Robert Tashjian, Principle Investigator, University of Utah
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 24, 2022